Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correspondence: A two-step algorithm for pharmacologic management of COPD: Bridging foundational and personalized medicine.

Respiratory medicine·2026

Same author

Association Between Chronic PM2.5 Exposure and CT-Detected Lung Abnormalities in the SPIROMICS Cohort.

Annals of the American Thoracic Society·2026

Same author

The evolving science of ventilation heterogeneity: From pathophysiology to personalized therapeutic approaches.

Respiratory medicine·2026

Same author

Similarity of sputum mediator signatures between e-cigarette users and COPD depends on GOLD stage and type of e-cigarette: a pilot study.

PloS one·2026

Same author

ERS technical standard on reference values for cardiopulmonary exercise testing: summary report and a call for action.

The European respiratory journal·2026

Same author

Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing.

Journal of the American Heart Association·2026

Search research articles

Related Experiment Video

Updated: Apr 5, 2026

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

Positioning new pharmacotherapies for COPD.

Igor Z Barjaktarevic¹, Anthony F Arredondo¹, Christopher B Cooper²

¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

International Journal of Chronic Obstructive Pulmonary Disease

|August 6, 2015

Summary

New pharmacotherapies offer improved management for Chronic Obstructive Pulmonary Disease (COPD). This review details established and emerging treatments, including novel agents, to guide clinicians in optimizing patient care for this widespread respiratory condition.

Keywords:

COPD phenotypes LABA LAMA fixed-combination inhalers long-acting muscarinic antagonist long-acting β-2 sympathomimetic agonist once-daily inhalers

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Related Experiment Videos

Last Updated: Apr 5, 2026

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Area of Science:

Pulmonology
Pharmacology

Background:

Chronic Obstructive Pulmonary Disease (COPD) presents a significant global health challenge, impacting morbidity and mortality.
Current management guidelines address disease severity but may not fully capture COPD's phenotypic diversity.

Purpose of the Study:

To review recent advancements in COPD pharmacotherapy.
To compare existing treatments with novel and emerging drug classes.

Main Methods:

Literature review of established and new COPD pharmacotherapies.
Analysis of long-acting muscarinic antagonists, long-acting β-2 sympathomimetic agonists, fixed-dose combinations, inhaled corticosteroids, phosphodiesterase inhibitors, and targeted anti-inflammatory drugs.
Inclusion of oral medications and agents in early development.

Main Results:

The review covers a broad spectrum of pharmacotherapies for COPD management.
Evidence on the efficacy and safety of new medications is presented.
Guidance is offered on the appropriate use of novel therapies.

Conclusions:

A wider array of pharmacotherapies is becoming available for COPD.
Clinicians need to be familiar with new agents to tailor treatment to individual patient needs and phenotypes.
Optimizing COPD management requires understanding the evidence for emerging treatments.